HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

S 0139 (97-139)

Subscribe to New Research on S 0139

structure given in first source; ET(A) receptor antagonist

Also Known As:

97-139; 27-O-3-(2-(3-carboxyacryloylamino)-5-hydroxyphenyl)acryloyloxymyricerone, sodium salt; S-0139

Networked: 11 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Terpenes: 260
    - Triterpenes: 141
      - Pentacyclic Triterpenes: 30
        Oleanolic Acid: 228
        S 0139: 11
      - Sapogenins: 13
        Oleanolic Acid: 228
        S 0139: 11
- Carboxylic Acids: 83
  - Carbocyclic Acids
    - Cinnamates: 10
      - Caffeic Acids: 5
        S 0139: 11

Experts

1.	Nadarajah, N: 1 article (07/2014)
2.	Bacher, U: 1 article (07/2014)
3.	Alpermann, T: 1 article (07/2014)
4.	Krauth, M-T: 1 article (07/2014)
5.	Haferlach, T: 1 article (07/2014)
6.	Eder, C: 1 article (07/2014)
7.	Schnittger, S: 1 article (07/2014)
8.	Kern, W: 1 article (07/2014)
9.	Haferlach, C: 1 article (07/2014)
10.	Hassn, A: 1 article (08/2010)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 09/01/2001 - "Furthermore, posttreatment with S-0139 significantly attenuated the increased Evans blue dye-quantified albumin extravasation and improved the mortality of animals after cerebral ischemia/reperfusion. "
2.	Brain Injuries (Brain Injury) 09/01/2001 - "Our data demonstrate that infusion with S-0139, an ET(A) antagonist, results in significant reduction of brain injury and plasma extravasation after transient MCAO. "
3.	Stroke (Strokes) 10/01/2008 - "Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke." 07/01/2002 - "Shionogi and GlaxoSmithKline (GSK), as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals LLC, are developing S-0139 (SB-737004), an endothelin-A (ETA) antagonist, for the potential treatment of hemorrhagic and ischemic stroke [223386], [252007], [426822], [426830]. " 10/01/2008 - "Using a model of embolic stroke, the present study tested the hypothesis that blockage of endothelin-1 with S-0139, a specific endothelin type A receptor (ET(A)) antagonist, enhances the neuroprotective effect of recombinant tissue plasminogen activator (rtPA) by suppressing molecules that mediate thrombosis and blood brain barrier (BBB) disruption induced by ischemia and rtPA. "
4.	Thrombosis (Thrombus) 10/01/2008 - "These data suggest that S-0139 provides the neuroprotection by suppressing ischemia- and rtPA-triggered molecules that evoke thrombosis and BBB disruption." 10/01/2008 - "Using a model of embolic stroke, the present study tested the hypothesis that blockage of endothelin-1 with S-0139, a specific endothelin type A receptor (ET(A)) antagonist, enhances the neuroprotective effect of recombinant tissue plasminogen activator (rtPA) by suppressing molecules that mediate thrombosis and blood brain barrier (BBB) disruption induced by ischemia and rtPA. "
5.	Ischemia 10/01/2008 - "These data suggest that S-0139 provides the neuroprotection by suppressing ischemia- and rtPA-triggered molecules that evoke thrombosis and BBB disruption." 10/01/2008 - "Using a model of embolic stroke, the present study tested the hypothesis that blockage of endothelin-1 with S-0139, a specific endothelin type A receptor (ET(A)) antagonist, enhances the neuroprotective effect of recombinant tissue plasminogen activator (rtPA) by suppressing molecules that mediate thrombosis and blood brain barrier (BBB) disruption induced by ischemia and rtPA. "

Related Drugs and Biologics

1.	Evans Blue (Blue, Evans)
2.	Endothelins (Endothelin)
3.	Endothelin-1 (Endothelin 1)
4.	Tissue Plasminogen Activator (Alteplase)
5.	Endothelin A Receptor
6.	Endothelin Receptors (Endothelin Receptor)
7.	Congenital amegakaryocytic thrombocytopenia
8.	glucuronyl glucosamine glycan sulfate (Vessel)